Bahrain vs Eastern and South-Eastern Asia: Percentage of bloodstream infection due to Escherichia coli resistant
Bahrain
63.0%
in 2022
Eastern and South-Eastern Asia
41.4%
in 2022
Bahrain rank
9th
Eastern and South-Eastern Asia rank
12th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Bahrain
- Eastern and South-Eastern Asia
How they compare
Bahrain currently reports 63.0% against 41.4% in Eastern and South-Eastern Asia, a difference of 21.6%.
That makes Bahrain's figure about 1.5 times Eastern and South-Eastern Asia's.
Across all 5 years both countries report, Bahrain has been ahead every year.
Bahrain ranks 9th and Eastern and South-Eastern Asia ranks 12th of 50 countries.
Bahrain has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bahrain | Eastern and South-Eastern Asia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 49.0% | 34.9% | 14.1% | Bahrain |
| 2020s | 60.4% | 39.4% | 21.0% | Bahrain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Bahrain or Eastern and South-Eastern Asia?
- Bahrain, at 63.0% against 41.4% in Eastern and South-Eastern Asia as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Bahrain and Eastern and South-Eastern Asia?
- 21.6%, with Bahrain ahead.
- How many years of comparable data are there for Bahrain and Eastern and South-Eastern Asia?
- 5 years are reported by both, from 2017 to 2022.
- How do Bahrain and Eastern and South-Eastern Asia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Bahrain ranks 9th and Eastern and South-Eastern Asia ranks 12th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.